Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $346,080.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 14,000 shares of the business’s stock in a transaction dated Thursday, April 11th. The shares were sold at an average price of $24.72, for a total transaction of $346,080.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Wednesday, March 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.25, for a total transaction of $59,312.50.
• On Tuesday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.97, for a total value of $55,152.50.
• On Monday, January 29th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $15.81, for a total value of $51,382.50.

Enliven Therapeutics Price Performance

ELVN opened at $17.30 on Thursday. The stock has a market capitalization of $712.76 million, a price-to-earnings ratio of -7.90 and a beta of 1.06. The business has a 50-day moving average of $16.98 and a two-hundred day moving average of $14.31. Enliven Therapeutics, Inc. has a 12 month low of $9.80 and a 12 month high of $26.00.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.09. Equities research analysts anticipate that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current year.

Institutional Trading of Enliven Therapeutics

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Enliven Therapeutics by 6.9% during the 4th quarter. Vanguard Group Inc. now owns 1,230,888 shares of the company’s stock worth $17,035,000 after purchasing an additional 79,071 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Enliven Therapeutics by 28.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 22,698 shares of the company’s stock worth $314,000 after purchasing an additional 5,008 shares during the period. Barclays PLC grew its holdings in shares of Enliven Therapeutics by 208.7% during the 4th quarter. Barclays PLC now owns 42,078 shares of the company’s stock worth $583,000 after purchasing an additional 28,449 shares during the period. Citadel Advisors LLC grew its holdings in shares of Enliven Therapeutics by 1.8% during the 4th quarter. Citadel Advisors LLC now owns 2,394,448 shares of the company’s stock worth $33,139,000 after purchasing an additional 42,782 shares during the period. Finally, Royal Bank of Canada grew its holdings in shares of Enliven Therapeutics by 69.8% during the 4th quarter. Royal Bank of Canada now owns 7,991 shares of the company’s stock worth $110,000 after purchasing an additional 3,284 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Mizuho initiated coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price target for the company.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.